Ratio Therapeutics的动态

The precision of LC-MS/MS is a game-changer in the development of antibody-drug conjugates (ADCs), essential for advancing oncology. By providing a detailed analysis of ADC components, LC-MS/MS ensures that new treatments are effective and safe for patients. Explore how this powerful analytical tool is paving the way for better cancer treatment outcomes. #CancerResearch #LCMS #ADCs #Biotechnology https://hubs.li/Q02GcTHJ0

This study presents a 3D pancreatic cancer model that tracks pH changes in the tumor environment during drug treatment, revealing how metabolic shifts, like extracellular acidification, can impact therapy effectiveness https://ow.ly/OwOV50Ui2mC

Another exciting collaboration with C&EN BrandLab! This article explores the transformative role of small molecule oncology drugs in cancer treatment, highlighting how innovative approaches are overcoming therapeutic challenges and advancing patient care. ??? The piece delves into the unique benefits of small molecules, recent breakthroughs in drug development, and how industry leaders like Lonza are helping to accelerate these innovations. A special thank you to Lonza's expert, Charlie Johnson, for sharing invaluable expertise and insights that brought this piece to life. Don’t miss it—check it out here: https://lnkd.in/emeMq_iC #LonzaSM #Oncology #Innovation #SmallMolecules

Discover the transformative potential of antibody-drug conjugates (ADCs) in targeted cancer therapy. Our latest presentation dives deep into the journey of ADC development, from Paul Ehrlich's early concept of "magic bullets" to their current status as a leading treatment modality. Learn about the intricate bioanalytical challenges, cutting-edge techniques, and regulatory milestones shaping the future of ADCs in oncology. #CancerResearch #ADCs #Bioanalysis #PrecisionMedicine #WuXiAppTec https://hubs.li/Q02zVC290

Learn about the history and future of small molecule oncology drugs - big thanks to our friends at Lonza for the feature!

?? Major breakthrough! The FDA has approved Zihera, a groundbreaking cancer-treating antibody developed by Vancouver-based biotech company Zymeworks! ?? This approval marks a huge milestone for treating metastatic HER2-positive biliary tract cancer—a rare and deadly form of GI cancer. This game-changing treatment offers hope where chemotherapy has failed, showing significant tumor shrinkage in clinical trials. ???? We’re celebrating this success and the incredible innovations coming out of Canada’s biotech sector. ???? Read More: https://lnkd.in/gygUvQw5 #PharmaInnovation #FDAApproval #CancerResearch #Zymeworks #Biotech #TorontoInstituteOfPharmaceuticalTechnology #MedicalBreakthroughs #Her2Positive #HealthTech

????Exciting news: ExpreS2ion Biotechnologies announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer! ?? ? Read the news here: https://lnkd.in/dUgu2ZaX ? #Biotech #BreastCancerResearch #Innovation #ExpreS2ionBiotechnologies #BreastCancerVaccine #CancerVaccine #FightBreastCancer #CancerAwareness #CancerTreatment #HER2Positive #ClinicalTrials #MedicalResearch #VaccinesSaveLives?

The first patient has been dosed in our #clinicaltrial collaboration with Merck KGaA, Darmstadt, Germany. The combination therapy is being evaluated in a Phase 2 cohort for treatment of non-small cell lung cancer.?? ? “We are excited to move forward with evaluating this combination therapy in a clinical setting after seeing encouraging synergy with AU-007 in preclinical studies. We thank Merck KGaA, Darmstadt, Germany, the patients and the clinical trial investigators who have chosen to participate in this clinical trial,” said CEO Aron Knickerbocker.?? ? Learn more here: https://bit.ly/3Z8IddJ ? #clinicaltrials #biopharma?

Explore the latest oncology innovations: New analysis of 5,000+ Commercial Opportunity Projects from over 100 leading universities worldwide. Book your 30 min demo here: https://lnkd.in/dii3FECB #cancer #oncology #cancerresearch #drugdiscovery #drugdevelopment #1stoncology #biotech #pharma #immunooncology #clinicaltrials #academic #businessdevelopment #searchandevaluation #commercialopportunities

Our latest article explores how LC-MS/MS revolutionizes the analysis of antibody-drug conjugates (ADCs), offering a perfect blend of precision, speed, and cost savings. Learn how this method stands out in the fast-paced world of cancer therapeutics. #ADCDrugs #LCMS #BioassayOptimization #DrugDevelopment #CancerResearch https://hubs.li/Q02JGgl-0